Your Position:Products>Monoclonals/Polyclonals

Anti-Human IL-3R alpha & CD3 epsilon Bispecific Reference Antibody

货号:RB9THB714036
  • Price:Negotiable
  • Click:455

Product Detail

Product Details

FormLiquid
Host SpeciesChimeric
ClonalityMonoclonal
IsotypeIgG1-kappa/scFv-h-CH2-CH3
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetIL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberP26951 & P07766
BackgroundVibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.<br>
Alternative NamesBispecific, XmAb14045, 2138442-13-2
NoteFor research use only. Not suitable for clinical or therapeutic use.